SCHEMBL19686897

SCHEMBL19686897

Cc1csc(-c2nc(Cl)cc(NC3CCC(F)(F)CC3)n2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 16/20 0.48
IDH2 P48735 3/20 0.42
CDC7 O00311 2/20 0.34
CHEK1 O14757 2/20 0.34
MAPK13 O15264 2/20 0.34
PDPK1 O15530 2/20 0.34
DAPK3 O43293 2/20 0.34
DYRK3 O43781 2/20 0.34
PAK4 O96013 2/20 0.34
CHEK2 O96017 2/20 0.34
EGFR P00533 2/20 0.34
PRKCG P05129 2/20 0.34
CDK1 P06493 2/20 0.34
ROS1 P08922 2/20 0.34
FER P16591 2/20 0.34
PRKACA P17612 2/20 0.34
RPS6KB1 P23443 2/20 0.34
MARK3 P27448 2/20 0.34
FLT4 P35916 2/20 0.34
PRKCI P41743 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21143909 0.91 IDH1 (0.47) IDH1IDH2FABP4FABP5
SCHEMBL21143660 0.90 IDH1 (0.37) IDH1CDC7CHEK1MAPK13PDPK1
SCHEMBL31127343 0.90 IDH1 (0.37) IDH1CDC7CHEK1MAPK13PDPK1
SCHEMBL19686338 0.90 IDH1 (0.51) IDH1IDH2ADORA2AFABP4FABP5
SCHEMBL31127090 0.88 IDH1 (0.40) IDH1CDC7CHEK1MAPK13PDPK1
SCHEMBL21143735 0.88 IDH1 (0.40) IDH1CDC7CHEK1MAPK13PDPK1
SCHEMBL21165966 0.87 IDH1 (0.49) IDH1IDH2ADORA2AFABP4FABP5
SCHEMBL19686995 0.87 IDH1 (0.49) IDH1IDH2ADORA2AFABP4FABP5
SCHEMBL31127091 0.87 IDH1 (0.49) IDH1IDH2ADORA2AFABP4FABP5
SCHEMBL21143951 0.86 IDH1 (0.48) IDH1IDH2ADORA2AFABP4FABP5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2024-09-26 US disclosed
CN-110198935-B Potassium channel modulators 卡登特治疗公司 2022-05-31 CN disclosed
US-20210380571-A1 POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS INC (US) 2021-12-09 US disclosed
US-20210380571-A1 POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS INC (US) 2021-12-09 US disclosed
EP-3571193-B1 POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS INC (US) 2021-12-01 EP disclosed
EP-3571193-B1 POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS INC (US) 2021-12-01 EP disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-10717728-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-07-21 US disclosed
US-10717728-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-07-21 US disclosed
US-10351553-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2019-07-16 US disclosed
US-20180215746-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2018-08-02 US disclosed
US-20180215746-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2018-08-02 US disclosed
US-20180215746-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2018-08-02 US disclosed
WO-2018136917-A1 POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS, INC. (US) 2018-07-26 WO disclosed
WO-2018136917-A1 POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS, INC. (US) 2018-07-26 WO disclosed
US-9975886-B1 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975886-B1 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975886-B1 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
WO-2017139697-A9 BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA SYNLOGIC, INC. (US) 2017-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 IDH1 3017/4885IDH2 2447/4885CDC7 3353/4885
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 IDH1 3017/4885IDH2 2447/4885CDC7 3353/4885
US-20210380571-A1 POTASSIUM CHANNEL MODULATORS KCNJ2, KCNK10, KCNJ1 IDH1 2868/4885IDH2 2185/4885CDC7 3518/4885
US-10717728-B2 Potassium channel modulators KCNJ2, KCNQ2, KCNJ1 IDH1 2691/4885IDH2 2021/4885CDC7 3522/4885
US-20180215746-A1 POTASSIUM CHANNEL MODULATORS KCNJ2, KCNK10, KCNJ1 IDH1 2868/4885IDH2 2185/4885CDC7 3518/4885
US-10351553-B2 Potassium channel modulators KCNN2, KCNN1, KCNN3 IDH1 3070/4885IDH2 2137/4885CDC7 3210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.